Morgans sets AUD 230 target for Pro Medicus stock

Published on 10/20/2026 at 20:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pro Medicus carries a 69.19 price-to-earnings ratio on October 20, 2026. Pro Medicus stock costs EUR 111.17 on October 20, 2026.

Analyst target and reporting date

Morgans analyst Iain Wilkie set an AUD 230.00 target on October 20, 2026.
Pro Medicus reported AUD 261.70 million in fiscal year 2026 revenue, up 22.90 percent year over year.
Pro Medicus stock costs EUR 111.17 at Lang & Schwarz on October 20, 2026 at 8:11 p.m. CEST.
The annual general meeting is scheduled for November 25, 2026.

Pro Medicus, AU000000PME8, Illustration mit AI erstellt.

Pro Medicus (ISIN AU000000PME8) has a fresh AUD 230.00 analyst target after Morgans analyst Iain Wilkie maintained a Buy rating on October 20, 2026, according to The Globe and Mail. On the Australian Securities Exchange, Pro Medicus was quoted at AUD 179.93 at 4:10 p.m. AEDT on October 20, 2026, putting the target 27.83 percent above that home-market price. At Lang & Schwarz, the stock was trading at EUR 111.17 on October 20, 2026 at 8:11 p.m. CEST.

Revenue growth remains substantial

Pro Medicus reported AUD 261.70 million in revenue for fiscal year 2026, up 22.90 percent from fiscal year 2025. Underlying profit rose 24.10 percent over the same period, according to the company information summarized by Simply Wall St. The latest annual figures keep operating growth at the center of the valuation discussion, while the target from Morgans points to a higher value than the current ASX quotation.

Stock stays below its yearly high

The ASX quotation stood 38.17 percent below the AUD 291.00 52-week high and 66.99 percent above the AUD 107.75 52-week low on October 20, 2026. The latest available market capitalization was AUD 18.80 billion, with a price-to-earnings ratio of 70.84 on the same quote. The stock's 2026 year-to-date performance was not used here because the available figures do not provide a consistent dated starting level.

How does valuation compare?

Pro Medicus carried a price-to-earnings ratio of 69.19 and a market capitalization of AUD 18.36 billion in the October 20, 2026 market snapshot reported by The Globe and Mail. The small difference from the live market figures reflects the separate quotation times. Pro Medicus is a healthcare information-services company whose Visage platform provides medical imaging software for hospitals and imaging groups, as stated on its Pro Medicus investor page.

Comparison with peers

Pro Medicus: price-to-earnings ratio 69.19, market capitalization AUD 18.80 billion.
Sectra: up 0.81 percent, price-to-earnings ratio 98.59, market capitalization SEK 62.12 billion.
Tempus AI: up 6.94 percent, market capitalization USD 12.07 billion.

When is the next company date?

Pro Medicus is scheduled to hold its annual general meeting on November 25, 2026, according to Simply Wall St. The meeting is the next dated corporate event identified for shareholders.

Target leaves a wide valuation gap

The AUD 230.00 Morgans target is AUD 50.07 above the October 20 ASX price of AUD 179.93. That 27.83 percent gap gives investors a clear numerical measure of the target, while the 69.19 price-to-earnings ratio highlights how much future growth is already embedded in the valuation. The company continues to combine high reported growth with a demanding market multiple.

Pro Medicus was trading at EUR 111.17 at Lang & Schwarz on October 20, 2026 at 8:11 p.m. CEST.